次世代抗体療法の世界市場:抗体薬物複合体(ADC)、エンジニアード抗体、二重特異性抗体、抗体断片/ALP、バイオシミラー抗体

◆英語タイトル:Next-Generation Antibody Therapies Market Forecast 2015-2025 : Opportunities for Leading Companies in ADCs, Engineered Antibodies, ALPs and Biosimilar Antibodies
◆商品コード:VGAIN5052606
◆発行会社(調査会社):visiongain
◆発行日:2015年5月
◆ページ数:236
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserGBP1,799 ⇒換算¥248,262見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥413,862見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥689,862見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、次世代抗体療法の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・次世代抗体療法の世界市場
 (市場規模予測、市場の成長要因・阻害要因など)
・次世代抗体療法の世界市場:セグメント別市場分析
 - 抗体薬物複合体(ADC)
 - エンジニアード抗体
 - 二重特異性抗体
 - 抗体断片/ALP
 - バイオシミラー抗体
・地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論
【レポートの概要】

Next-generation antibody therapies – new study showing you trends, R&D progress, and predicted revenues
Where’s the next-generation antibody therapies market heading? Visiongain’s brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.

Our 236-page report provides 126 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharmaceutical market.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments. Read the full transcripts of three exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Dr Edwin Moses, CEO, Ablynx
- Tim Van Hauwermeiren , CEO, ArGEN-X
- The executive management team at Mersana Therapeutics

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you see revenue forecasts to 2025 for the following submarkets:
• Antibody-drug conjugates (ADCs)
• Engineered antibodies
• Bispecific antibodies
• Antibody fragments and antibody-like proteins (ALPs)
• Biosimilar antibodies

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products
How will leading next-generation antibody therapies perform to 2025 at world level? Our study forecasts sales of 7 products, including these brands:
• Adcetris
• Kadcyla
• Gazyva/Gazyvaro
• Poteligeo
• Removab
• Blincyto
• Kalbitor

Discover how high revenues can go. You see what’s happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 5 regional markets to 2025:
• US
• EU5
• Asia-Pacific
• Latin America
• Rest of the World

There will be growth in established pharma markets and in developing countries. Our analyses show that the Asia-Pacific, in particular, will continue to achieve high revenue growth to 2025. Developments worldwide in biosimilar regulation and next-generation antibody development will influence the market.

Leading companies and potential for market growth
Overall world revenue for next-generation antibody therapies will reach $2.3bn in 2015, our work forecasts. We predict strong revenue growth through to 2025. Market entry of novel therapies, investment from Big Pharma and increasing demand for chronic disease treatment will increase sales to 2025.

Our work shows you what organisations hold greatest potential. Discover capabilities, progress, and commercial prospects, helping you stay ahead.

Research and development – assess innovation, trends and possibilities
What about R&D – the pipeline for new drugs? You see trends for these areas:
• Antibody-drug conjugates (ADCs)
• Engineered antibodies
• Bispecific antibodies
• Antibody fragments and antibody-like proteins (ALPs)
• Other progress in next-generation antibody therapy development.


Our study also discusses these agents and technologies, among others:
• Site-specific linkers
• Glycosylation or glycoengineering
• Defucosylation
• Amino acid modification
• Enhanced antibody-dependent cell-mediated cytotoxicity (ADCC)
• Bispecific, trispecific and multi-specific antibodies
• Domain fragments
• Single-chain variable fragments
• Alternative scaffolds: DARPins, anticalins, Affibodies, Fynomers, Affilins, Adnectins and i-bodies
• Combination therapies
• Other novel antibody platforms

Next-generation antibody therapy R&D is strong in antibody-drug conjugates. Novel products and biobetters with high safety, efficacy and affordability are in great demand. Our work explains, discussing many issues.

【レポートの目次】

1. Report Overview
1.1 Global Next-Generation Antibody Therapies Market Overview
1.2 Global Next-Generation Antibody Therapies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Next-Generation Antibody Therapies
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 Antibodies: An Overview
2.2.1 Monoclonal versus Polyclonal Antibodies
2.2.2 A Brief History of Antibody Drug Development
2.2.3 The Antibody Manufacturing Process
2.2.4 Trends in Antibody Development
2.3 Defining Next-Generation Antibodies
2.3.1 Classification of Next-Generation Antibody Therapies
2.3.2 The Need for Next-Generation Technologies
2.4 Development Trends for Next-Generation Antibodies
2.5 Phases of Clinical Trials
2.6 Scope of this Report
2.7 Currency Exchange Rates in This Report

3. Next-Generation Antibody Therapies: World Market 2015-2025
3.1 The World Next-Generation Antibody Therapies Market in 2014
3.1.1 Next-Generation Antibody Therapies Market Segmentation, 2014
3.1.2 Leading Next-Generation Antibody Therapies Products
3.2 World Next-Generation Antibody Therapies Market: Sales Forecast 2015-2025
3.3 How Will Segmental Market Shares Change to 2025?
3.4 World Next-Generation Antibody Therapies Market: Drivers and Restraints 2015-2025

4. Leading Regional Markets 2015-2025
4.1 Regional Breakdown of the World Next-Generation Antibody Therapies Market
4.2 World Next-Generation Antibody Therapies Market: Regional Forecast 2015-2025
4.3 How Will Regional Market Shares Change to 2025?
4.4 US Next-Generation Antibody Therapies Market 2015-2025
4.5 EU5 Next-Generation Antibody Therapies Market 2015-2025
4.6 Asia-Pacific Next-Generation Antibody Therapies Market 2015-2025
4.7 Latin American Next-Generation Antibody Therapies Market 2015-2025
4.8 The Next-Generation Antibody Therapies Market in the Rest of the World 2015-2025

5. Antibody-Drug Conjugates: Market Forecast and Pipeline 2015-2025
5.1 Antibody-Drug Conjugates: Market Overview, 2015
5.2 Leading ADCs in 2015
5.3 Antibody-Drug Conjugates: Market Forecast 2015-2025
5.4 The Antibody-Drug Conjugates Market: Drivers and Restraints 2015-2025
5.4.1 Competition for Leading Drugs Will Restrain Growth in 2015-2025
5.4.2 Manufacturing ADCs Forms a Challenge
5.5 Adcetris (brentuximab vedotin, Seattle Genetics/Takeda)
5.5.1 Adcetris: Sales Forecast 2015-2025
5.5.2 Adcetris Meets Primary Endpoint in AETHERA Trial
5.5.3 Expanding Adcetris Indications for Future Revenue Growth
5.6 Kadcyla (trastuzumab emtansine, Roche)
5.6.1 Kadcyla: Sales Forecast 2015-2025
5.6.2 Phase 3 Results for Kadcyla/Perjeta Combination Disappoint
5.7 Mylotarg (gemtuzumab ozogamicin, Pfizer)
5.7.1 Mylotarg to be Relaunched?
5.8 Antibody-Drug Conjugate Platforms
5.8.1 Limited Market Opportunity for Radioconjugation
5.8.2 Seattle Genetics’ Platform Accounts for Over 50% of the Pipeline
5.8.3 ImmunoGen: TAP Technology
5.8.4 Immunomedics: Lower Potency Cytotoxics for Extended Use
5.8.5 Preclinical Platforms for ADC Development
5.9 ADCs Are Attracting High-Value Deals
5.10 Antibody-Drug Conjugates: Pipeline Analysis 2015-2025
5.10.1 The Longest Pipeline in the Next-Generation Antibodies Market
5.10.2 Cancer Is the Only Target for Current Clinical-Stage ADCs
5.11 Antibody-Drug Conjugates: Phase 3 Pipeline
5.11.1 CMC544 (inotuzumab ozogamicin, Pfizer)
5.11.2 Roche Attempts to Expand Kadcyla’s Breast Cancer Indication
5.11.2.1 RG7596 (polatuzumab vedotin) for NHL and DLBCL
5.11.2.2 RG7599/DNIB0600A (anti-NaPi2b) for Ovarian Cancer
5.11.2.3 RG7450/DSTP3086S (anti-STEAP1) for Prostate Cancer
5.12 Antibody-Drug Conjugates: Phase 2 Pipeline
5.12.1 ABT-414 (anti-EGFR, AbbVie/Seattle Genetics)
5.12.2 BT-062 (indatuximab ravtansine; anti-CD138, Biotest)
5.12.3 CDX-011 (glembatumumab vedotin; anti-glycoprotein NMB, Celldex Therapeutics/Seattle Genetics)
5.12.4 Immunomedics’ IMMU-130 (labetuzumab-SN-38; anti-CEA/CD66e) and IMMU-132 (anti-TROP-2)
5.12.5 MLN0264 (anti-GCC, Millennium Pharmaceuticals/Seattle Genetics)
5.12.6 MM-302 (anti-HER2, Merrimack Pharmaceuticals)
5.12.7 PSMA ADC (anti-PSMA, Progenics Pharmaceuticals/Seattle Genetics)
5.12.8 SAR3419 (coltuximab ravtansine) (anti-CD19, Sanofi)
5.12.9 Seattle Genetics’ Phase 1 and Phase 2 ADCs
5.12.9.1 SGN-CD19A (anti-CD19) for DLBCL and ALL
5.12.9.2 SGN-LIV1A (anti-LIV-1) for Relapsed Breast Cancer
5.12.9.3 SGN-CD33A: Using a New Cytotoxin and Linker Technology
5.12.9.4 SGN-CD70A (anti-CD70, Seattle Genetics)
5.13 Antibody-Drug Conjugates: Phase 1 Pipeline
5.13.1 Astellas Pharma: Partnered with Seattle Genetics for Phase 1 ADCs
5.13.2 Amgen’s AMG 595 (anti-EGFRv3) and AMG 172 (anti-CD27L)
5.13.3 Bayer’s Pipeline ADCs
5.13.3.1 Anetumab ravtansine (BAY 94-9343) (anti-mesothelin, Bayer)
5.13.3.2 C4.4a-ADC/BAY1129980 (anti-C4.4a, Bayer/Seattle Genetics)
5.13.3.3 FGFR2-ADC (anti-FGFR2, Bayer)
5.13.4 GSK2857916 (anti-BCMA, GSK/Seattle Genetics)
5.13.5 HuMax-TF-ADC (anti-TF, Genmab/Seattle Genetics)
5.13.6 ImmunoGen’s IMGN529 (anti-CD37), IMGN853 (anti-Folate receptor α) and IMGN289 (anti-EGFR)
5.13.7 LOP628 (anti-cKit, Novartis)
5.13.8 PF-06263507 (anti-5T4, Pfizer/Seattle Genetics)
5.13.9 Sanofi’s SAR408701 (anti-CEACAM5) and SAR566658 (anti-CA6)
5.13.10 SYD985 (trastuzumab duocarmycin; anti-HER2, Synthon)
5.14 Antibody-Drug Conjugates: Preclinical Pipeline
5.15 Future Developments in ADC Technology
5.15.1 Site-Specific Linkage for Improved Safety Profiles

6. Engineered Antibodies: Market Forecast and Pipeline 2015-2025
6.1 Engineered Antibodies: Market Overview, 2015
6.2 Leading Engineered Antibodies in 2015
6.3 Engineered Antibodies: Market Forecast 2015-2025
6.4 The Engineered Antibodies Market: Drivers and Restraints 2015-2025
6.5 Poteligeo (mogamulizumab, Kyowa Hakko Kirin)
6.5.1 Poteligeo: Sales Forecast 2015-2025
6.6 Gazyva/Gazyvaro (obinutuzumab, Roche)
6.6.1 Gazyva as a Challenger in the anti-CD20 Market
6.6.2 Competition beyond Rituxan and Biosimilars
6.6.3 Gazyva: Sales Forecast 2015-2025
6.7 Engineered Antibodies Platforms
6.7.1 Roche Glycart: GlucoMAb – Glycosylation for Improved ADCC
6.7.2 Kyowa Hakko Kirin: Potelligent – Enhancing ADCC
6.7.3 Glycotope: GlycoExpress
6.7.4 MacroGenics: Fc Optimization
6.7.5 Xencor: XmAb – Modifying Amino Acids in the Fc Domain
6.7.6 Other Platforms for Increased Potency
6.8 Engineered Antibodies: Pipeline Analysis 2015-2025
6.9 Engineered Antibodies: Phase 3 Pipeline
6.9.1 Benralizumab (MedImmune/Kyowa Hakko Kirin)
6.9.2 Elotuzumab (anti-SLAMF7, Bristol-Myers Squibb/AbbVie)
6.9.3 MEDI4736 (anti-PDL1, AstraZeneca)
6.9.4 RG7446/MPDL3280A (anti-PDL1, Roche)
6.9.5 Ublituximab (anti-CD20, TG Therapeutics)
6.10 Engineered Antibodies: Phase 2 Pipeline
6.10.1 Glycotope’s CetuGEX (anti-EGFR), PankoMab-GEX (anti-TA-MUC1) and TrasGEX (anti-HER2)
6.10.2 Margetuximab (anti-HER2, MacroGenics)
6.10.3 MEDI-551 (anti-CD19, AstraZeneca)
6.10.4 MOR-208 (XmAb5574) (anti-CD19, MorphoSys/Xencor)
6.10.5 Teplizumab (anti-CD3, MacroGenics)
6.10.6 BIW-8962 (anti-GM2, Kyowa Hakko Kirin)
6.10.7 XmAb5871 (anti-CD19, Xencor)
6.11 Engineered Antibodies: Phase 1 Pipeline
6.11.1 Ocaratuzumab (anti-CD20, Mentrik Biotech)
6.11.2 RG7116 (anti-HER3, Roche)
6.11.3 MGA271 (MacroGenics/Servier)

7. Bispecific Antibodies: Market Forecast and Pipeline 2015-2025
7.1 Bispecific Antibodies: Market Overview, 2015
7.2 Bispecific Antibodies: Market Forecast 2015-2025
7.3 The Bispecific Antibodies Market: Drivers and Restraints 2015-2025
7.3.1 Manufacturing Bispecific Antibodies: Maintaining Stability and Purification
7.4 Removab (catumaxomab, Neopharm)
7.4.1 Removab: Sales Forecast 2015-2025
7.5 Blincyto (blinatumomab, Amgen)
7.5.1 Blincyto: Sales Forecast 2015-2025
7.6 Bispecific Antibodies Platforms
7.6.1 BiTE Platform: The Current Market Leader
7.6.2 MacroGenics’ DART Platform Holds Promise
7.6.3 TriomAbs (TRION Pharma): Limited Market Impact 2014-2024
7.6.4 Other Bispecific Antibody Platforms
7.6.4.1 DuoBodies (Genmab)
7.6.4.2 ImmTAC (Immunocore)
7.7 Bispecific Antibodies: Pipeline Analysis 2015-2025
7.8 Bispecific Antibodies: Phase 2 and Phase 3 Pipeline
7.8.1 ABT-122 (anti-TNF and IL-17A) and ABT-981 (anti-IL-1α and IL-1β, AbbVie)
7.8.2 AFM13 (anti-CD30 and CD16A, Affimed Therapeutics)
7.8.3 MM-111 (anti-ErbB2 and ErbB3, Merrimack Pharmaceuticals)
7.8.4 MM-141 (anti-IGF-1R and ErbB3, Merrimack Pharmaceuticals)
7.8.5 SAR156597 (anti-IL-4 and IL-13, Sanofi)
7.8.6 Vanucizumab (RG7221; anti-Ang2 and VEGF-A, Roche)
7.9 Bispecific Antibodies: Phase 1 and Phase 1/2 Pipeline
7.9.1 COVA322 (anti-TNF and IL-17A, Johnson & Johnson)
7.9.2 IMCgp100 (anti-HLA-A2 and CD3, Immunocore)
7.9.3 Lymphomun (anti-CD20 and CD3, Trion Pharma/Fresenius Biotech)
7.9.4 MCLA-128 (anti-HER2 and HER3, Merus)
7.9.5 Rexomun (ertumaxomab) (anti-HER2 and CD3, Neopharm)
7.9.6 TF2 (anti-CEACAM5, Immunomedics)
7.9.7 AMG 211 (anti-CEA and CD3, Amgen/MedImmune)
7.9.8 BAY2010112 (MT112) (anti-PSMA and CD3, Bayer)
7.10 Bispecific Antibodies: Preclinical Pipeline

8. Antibody Fragments and Antibody-Like Proteins (ALPs): Market Forecast and Pipeline 2015-2025
8.1 Antibody Fragments and ALPs: Market Overview, 2015
8.2 Antibody Fragments and ALPs: Market Forecast 2015-2025
8.3 The Antibody Fragments and ALPs Market: Drivers and Restraints 2015-2025
8.4 Kalbitor (ecallantide, Dyax)
8.4.1 Kalbitor: Sales Forecast 2015-2025
8.5 Antibody Fragments and ALPs Platforms
8.5.1 Single-chain Variable Fragment Platforms
8.5.1.1 ESBATech and Delenex Therapeutics: Two Approaches Using the Same Platform
8.5.1.2 Nanobodies: The Smallest Antibody Fragment
8.5.1.3 Ablynx’s Nanobody Platform Has Created Many Clinical Candidates
8.5.1.4 Domain Antibodies: GSK and Crescendo Biologics
8.5.2 Non-Antibody Protein Scaffolds: Antibody-Like Proteins
8.5.2.1 DARPins: One-Tenth the Size of Antibodies
8.5.2.2 Anticalins (Pieris): Tested in Clinical Trials
8.5.2.3 Affibodies (Affibody)
8.5.2.4 Fynomers (Covagen/Johnson & Johnson)
8.5.2.5 Affilins (Scil Proteins): Three Products in Pre-Clinical Development?
8.5.2.6 Adnectins (Bristol-Myers Squibb)
8.5.2.7 AdAlta: i-bodies
8.5.3 Which Platform Will Lead the Market 2014-2024?
8.6 Antibody Fragments and ALPs: Pipeline Analysis 2015-2025
8.7 Antibody Fragments and ALPs: Phase 2 Pipeline
8.7.1 Ablynx Leads the Pipeline with Six Clinical Projects
8.7.1.1 Caplacizumab (anti-vWF)
8.7.1.2 ALX-0061 (anti-IL-6R, Ablynx/AbbVie)
8.7.1.3 Ozoralizumab (anti-TNFα)
8.7.1.4 ALX-0171 (anti-respiratory syncytial virus)
8.7.1.5 ALX-0141 (anti-RANKL, Ablynx/Eddingpharm)
8.7.1.6 ALX-0761 (anti-IL-17A and IL-17F, Ablynx/Merck Serono)
8.7.2 Abicipar (anti-VEGF, Allergan/Molecular Partners)
8.7.3 DLX105 (anti-TNF-α, Delenex Therapeutics)
8.7.4 ESBA1008 (anti-VEGF, Novartis)
8.8 Antibody Fragments and ALPs: Phase 1 Pipeline
8.9 Antibody Fragments and ALPs: Preclinical Pipeline

9. Biosimilar Antibodies: Market Forecast 2015-2025
9.1 Biosimilar Antibodies: Market Overview, 2015
9.2 Leading Biosimilar Antibodies in 2015
9.3 Biosimilar Antibodies: Market Forecast 2015-2025
9.4 The Biosimilar Antibodies Market: Drivers and Restraints 2015-2025
9.4.1.1 How Can Developers Ensure Uptake Among Physicians?
9.4.1.2 Automatic Substitution of Biosimilar Antibodies
9.4.1.3 Patent Expiries Will Hit Many Leading Antibodies in this Decade
9.4.1.4 Will Biosimilars Challenge Next-Generation Antibodies in this Decade?

10. Qualitative Analysis of the Next-Generation Antibody Therapies Market 2015-2025
10.1 SWOT Analysis of the Next-Generation Antibody Therapies Market
10.1.1 Strengths
10.1.1.1 Approved Products Indicate a Path to Market Acceptance
10.1.2 Weaknesses
10.1.2.1 Challenges Exist With Current Monoclonal Antibody Therapies
10.1.3 Opportunities
10.1.3.1 Big Pharma Is Investing Heavily in Next-Generation Pipelines
10.1.4 Threats
10.1.4.1 Will Biosimilars Slow Growth in the Next-Generation Antibody Market?
10.2 STEP Analysis of the Next-Generation Antibody Therapies Market
10.2.1 Social Factors: Rising Demand for Cancer Therapies
10.2.1.1 Cancer Incidence Is Rising Rapidly
10.2.1.2 Next-Generation Antibodies for Personalised Medicine
10.2.2 Technological Developments Will Drive Pipeline Growth
10.2.2.1 There Are Many Competing Platforms
10.2.2.2 Manufacturing Challenges Exist for Most Sectors
10.2.2.3 New Analytical Tools for Target Identification and Protein Characterisation
10.2.3 Economic Pressures
10.2.3.1 Next-Generation Antibodies Are High-Cost
10.2.3.2 Outsourced Manufacturing: CMOs Are Expanding Capabilities
10.2.3.3 Next-Generation Launches for Product Lifecycle Management
10.2.4 Political and Regulatory Issues
10.2.4.1 Regulatory Challenges for Biosimilar Antibodies
10.3 Key Targets for Next-Generation Antibody Development 2015-2025
10.3.1 Oncology Is the Lead Indication in All Sectors
10.3.1.1 HER2 and HER3 for Breast Cancer
10.3.1.2 CD19 and CD20 for Lymphoma and Leukaemia

11. Research Interviews
11.1 Interview with Dr. Edwin Moses, CEO, Ablynx, Belgium
11.1.1 The Benefits of Nanobodies over Traditional Antibody Therapies
11.1.2 Manufacturing Nanobodies
11.1.3 Turning Challenges to Advantages
11.1.4 Nanobodies Are Further Developed than Other Antibody Scaffolds
11.1.5 The Commercial Potential for Nanobodies
11.1.6 Next-Generation Antibodies in China and Other Emerging Markets
11.2 Interview with Tim van Hauwermeiren, CEO, ArGEN-X, the Netherlands and Belgium
11.2.1 ArGEN-X’s Development Pipeline
11.2.2 Enhancing the Activity of ARGX-111
11.2.3 ArGEN-X’s SIMPLE Antibody™ Platform
11.2.4 Commercial Prospects for ArGEN-X’s Antibodies
11.2.5 Plans for Growth
11.2.6 Opportunities and Challenges for Next-Generation Antibody Developers
11.2.7 Therapeutic Areas for Manufacturers of Antibody Therapies
11.2.8 Other Trends and Developments in the Market
11.3 Interview with Mersana Therapeutics, Cambridge, Massachusetts, USA
11.3.1 Mersana’s Development Pipeline
11.3.2 Advantages of the Fleximer Platform
11.3.3 Future Plans for Mersana
11.3.4 The Outlook for ADCs in 2015-2025

12. Conclusions
12.1 High Growth Potential in the Next-Generation Antibody Therapies Market in 2015-2025
12.2 The World Next-Generation Antibody Therapies Market in 2014
12.2.1 Current Leading Next-Generation Antibody Therapies Segments
12.2.2 Leading Novel Next-Generation Antibody Therapies
12.2.3 Leading Regional Markets
12.3 World Next-Generation Antibody Therapies Market Forecast 2015-2025
12.4 Next-Generation Antibody Therapies: Late-Stage Pipeline
12.5 The Future of the Next-Generation Antibody Therapies Market?
12.5.1 A Strong Phase 1 and Phase 2 Pipeline
12.5.2 Technology Platforms Will Continue to Attract Big Pharma Interest
12.5.3 Most Developers Continue to Target Cancer
12.5.4 Strategies for Growth in 2015-2025

13. Glossary

List of Tables
Table 1.1 Leading Regional Next-Generation Antibody Therapies Market Forecast 2015 ($m, AGR%)
Table 2.1 Monoclonal Antibody Types and Sources, 2015
Table 2.2 Clinical Trial Phases
Table 2.3 Currency Exchange Rates, 2014
Table 3.1 World Next-Generation Antibody Therapies Market: Revenue ($m) and Market Share (%) by Segment, 2014
Table 3.2 World Next-Generation Antibody Therapies Market Forecast: Revenue ($m), AGR (%), CAGR (%) by Segment, 2014-2025
Table 3.3 World Next-Generation Antibody Therapies Market: Market Share (%) by Segment, 2014, 2019 and 2025
Table 4.1 World Next-Generation Antibody Therapies Market: Revenues ($m) and Market Shares (%) by Region, 2014
Table 4.2 World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Region, 2014-2025
Table 4.3 Market Shares (%) of Leading Regional Next-Generation Antibody Therapies Markets, 2014, 2019 and 2025
Table 4.4 US Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.5 EU5 Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.6 Asia-Pacific Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.7 Latin American Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 4.8 Rest of the World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2014-2025
Table 5.1 ADC Market: Revenues ($m), AGR (%), CAGR (%) by Drug, 2009-2014
Table 5.2 ADC Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2014-2025
Table 5.3 Adcetris: Revenue ($m), AGR (%), CAGR (%) by Company, 2011-2013
Table 5.4 Seattle Genetics/Takeda: Adcetris Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 5.5 Roche: Kadcyla Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 5.6 ADC Pipeline by Platform and Phase, 2015
Table 5.7 ImmunoGen: Collaboration Revenue ($m), 2012-2014
Table 5.8 Selected Preclinical ADC Development Platforms, 2015
Table 5.9 ADC Pipeline by Indication and Phase, 2015
Table 5.10 Antibody-Drug Conjugates: Phase 3 Pipeline, 2015
Table 5.11 Ongoing Clinical Trials for Inotuzumab Ozogamicin, 2015
Table 5.12 Roche's Antibody-Drug Conjugates Pipeline, 2015
Table 5.13 Antibody-Drug Conjugates: Phase 2 Pipeline, 2015
Table 5.14 Antibody-Drug Conjugates: Phase 1 Pipeline, 2015
Table 5.15 Antibody-Drug Conjugates: Preclinical Pipeline, 2015
Table 6.1 Engineered Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2014-2025
Table 6.2 Kyowa Hakko Kirin: Poteligeo Revenue ($m), AGR (%), 2012-2013
Table 6.3 Kyowa Hakko Kirin: Poteligeo Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 6.4 Roche: Gazyva/Gazyvaro Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 6.5 Engineered Antibodies Pipeline by Company and Phase, 2015
Table 6.6 Selected Licensing Agreements for the Potelligent Platform and Cell Lines, 2008-2014
Table 6.7 Engineered Antibodies Pipeline by Indication and Phase, 2015
Table 6.8 Engineered Antibodies: Phase 3 Pipeline, 2015
Table 6.9 Engineered Antibodies: Phase 2 Pipeline, 2015
Table 6.10 Engineered Antibodies: Phase 1 Pipeline, 2015
Table 7.1 Bispecific Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2014-2025
Table 7.2 Neopharm: Removab Revenue ($m), AGR (%), CAGR (%), 2010-2013
Table 7.3 Neopharm: Removab Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.4 Amgen: Blincyto Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 7.5 Bispecific Antibodies Pipeline by Company and Phase, 2015
Table 7.6 Selected Preclinical Bispecific Antibody Platforms, 2015
Table 7.7 Bispecific Antibodies Pipeline by Indication and Phase, 2015
Table 7.8 Bispecific Antibodies: Phase 2 and Phase 3 Pipeline, 2015
Table 7.9 Bispecific Antibodies: Phase 1/2 Pipeline, 2015
Table 7.10 Bispecific Antibodies: Phase 1 Pipeline, 2015
Table 7.11 Bispecific Antibodies: Preclinical Pipeline, 2015
Table 8.1 Antibody Fragments and ALPs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2014-2025
Table 8.2 Dyax: Kalbitor Revenue ($m), AGR (%), CAGR (%), 2010-2013
Table 8.3 Dyax: Kalbitor Revenue ($m), AGR (%), CAGR (%), 2014-2025
Table 8.4 Ablynx: Selected Big Pharma Collaboration Agreements, 2012-2015
Table 8.5 Antibody Fragments and ALPs Pipeline by Company and Phase, 2015
Table 8.6 Antibody Fragments and ALPs Pipeline by Indication and Phase, 2015
Table 8.7 Antibody Fragments and ALPs: Phase 2 Pipeline, 2015
Table 8.8 Antibody Fragments and ALPs: Phase 1 Pipeline, 2015
Table 8.9 Antibody Fragments and ALPs: Preclinical Pipeline, 2015
Table 9.1 Leading Biological Drugs by Revenue ($m) in 2014
Table 9.2 Biosimilar Antibodies Approved Worldwide, 2015
Table 9.3 Biosimilar Antibodies Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Drug, 2014-2025
Table 9.4 Patent Expiries for Leading Antibody Therapies in the US, EU and Japan, 2013-2022
Table 10.1 Next-Generation Antibody Therapies Market: STEP Analysis, 2015-2025
Table 10.2 Selected CMOs Investing in Next-Generation Antibody Technologies, 2005-2015
Table 10.3 HER2 and HER3-Targeting Next-Generation Antibodies: Pipeline, 2015
Table 10.4 CD19 and CD20-Targeting Next-Generation Antibodies: Pipeline, 2015
Table 12.1 Next-Generation Antibody Therapies Late-Stage Pipeline, 2015
Table 12.2 Next-Generation Antibody Therapies Pipeline by Phase, 2015

List of Figures
Figure 1.1 Next-Generation Antibody Therapies Pipeline by Phase (%), 2015
Figure 1.2 Global Next-Generation Antibody Therapies Market Segmentation Overview, 2015
Figure 2.1 Diagram of Antibody Structure, 2015
Figure 3.1 World Next-Generation Antibody Therapies Market: Market Share (%) by Segment, 2014
Figure 3.2 World Next-Generation Antibody Therapies Market Forecast: Revenue ($m) by Segment, 2014-2025
Figure 3.3 World Next-Generation Antibody Therapies Market: Market Share (%) by Segment, 2019
Figure 3.4 World Next-Generation Antibody Therapies Market: Market Share (%) by Segment, 2025
Figure 3.5 World Next-Generation Antibody Therapies Market: Drivers and Restraints, 2015-2025
Figure 4.1 World Next-Generation Antibody Therapies Market: Revenues ($m) by Region, 2014
Figure 4.2 World Next-Generation Antibody Therapies Market: Market Shares (%) by Region, 2014
Figure 4.3 World Next-Generation Antibody Therapies Market Forecast: Revenues ($m) by Region, 2014-2025
Figure 4.4 World Next-Generation Antibody Therapies Market: Market Shares (%) by Region, 2019
Figure 4.5 World Next-Generation Antibody Therapies Market: Market Shares (%) by Region, 2025
Figure 4.6 US Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 4.7 EU5 Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 4.8 Asia-Pacific Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 4.9 Latin American Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 4.10 Rest of the World Next-Generation Antibody Therapies Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.1 ADC Market: Revenues ($m) by Drug, 2009-2014
Figure 5.2 ADC Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 5.3 ADC Market: Drivers and Restraints, 2015-2025
Figure 5.4 Adcetris: Revenue ($m), AGR (%) by Company, 2011-2013
Figure 5.5 Seattle Genetics/Takeda: Adcetris Revenue ($m), AGR (%), 2014-2025
Figure 5.6 Roche: Kadcyla Revenue ($m), AGR (%), 2014-2025
Figure 5.7 ADC Pipeline by Platform, 2015
Figure 5.8 ADC Pipeline by Phase, 2015
Figure 5.9 ADC Pipeline by Indication, 2015
Figure 6.1 Engineered Antibodies Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 6.2 Engineered Antibodies Market: Drivers and Restraints, 2015-2025
Figure 6.3 Kyowa Hakko Kirin: Poteligeo Revenue ($m), AGR (%), 2012-2013
Figure 6.4 Kyowa Hakko Kirin: Poteligeo Revenue ($m), AGR (%), 2014-2025
Figure 6.5 Roche: Gazyva/Gazyvaro Revenue ($m), AGR (%), 2014-2025
Figure 6.6 Engineered Antibodies Pipeline by Company, 2015
Figure 6.7 Engineered Antibodies Pipeline by Indication, 2015
Figure 6.8 Engineered Antibodies Pipeline by Phase, 2015
Figure 7.1 Bispecific Antibodies Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 7.2 Bispecific Antibodies Market: Drivers and Restraints, 2015-2025
Figure 7.3 Neopharm: Removab Revenue ($m), AGR (%), 2010-2013
Figure 7.4 Neopharm: Removab Revenue ($m), AGR (%), 2014-2025
Figure 7.5 Amgen: Blincyto Revenue ($m), AGR (%), 2014-2025
Figure 7.6 Bispecific Antibodies Pipeline by Company, 2015
Figure 7.7 Bispecific Antibodies Pipeline by Indication, 2015
Figure 7.8 Bispecific Antibodies Pipeline by Phase, 2015
Figure 8.1 Antibody Fragments and ALPs Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 8.2 Antibody Fragments and ALPs Market: Drivers and Restraints, 2015-2025
Figure 8.3 Dyax: Kalbitor Revenue ($m), AGR (%), 2010-2013
Figure 8.4 Dyax: Kalbitor Revenue ($m), AGR (%), 2014-2025
Figure 8.5 Antibody Fragments and ALPs Pipeline by Company, 2015
Figure 8.6 Antibody Fragments and ALPs Pipeline by Indication, 2015
Figure 8.7 Antibody Fragments and ALPs Pipeline by Phase, 2015
Figure 9.1 Biosimilar Antibodies Market Forecast: Revenues ($m), AGR (%), 2014-2025
Figure 9.2 Biosimilar Antibodies Market: Drivers and Restraints, 2015-2025
Figure 10.1 Next-Generation Antibody Therapies Market: Strengths and Weaknesses, 2015-2025
Figure 10.2 Next-Generation Antibody Therapies Market: Opportunities and Threats, 2015-2025
Figure 12.1 Next-Generation Antibody Approvals, 2007-2015
Figure 12.2 Next-Generation Antibody Therapies Pipeline by Phase (%), 2015

【掲載企業】

AbbVie
Abgenix (part of Amgen)
Ablynx
Actavis
AdAlta
ADC Therapeutics
Adnexus (acquired by Bristol-Myers Squibb)
Affibody
Affimed Therapeutics
Agensys
Albany Molecular Research Inc. (AMRI)
Alcon (subsidiary of Novartis)
Alexion
Allergan
Ambrx
Amgen
Applied Molecular Evolution (acquired by Eli Lilly)
Arana Therapeutics (part of Teva)
ArGEN-X
Astellas Pharma
AstraZeneca
Bayer
Bioceros
Biocon
Biogen Idec
BioNet Ventures
Biotest
BioWa (subsidiary of Kyowa Hakko Kirin)
Boehringer Ingelheim
Bristol-Myers Squibb
Catalent Pharma Solutions
Celgene
Celldex Therapeutics
Celltech (part of UCB)
Celltrion
Cephalon (part of Teva)
Chugai
Cilag (part of Johnson & Johnson)
Coldstream Laboratories (acquired by Piramal)
Concortis Biosystems (acquired by Sorrento Therapeutics)
Corixa (acquired by GSK)
Covagen
Crescendo Biologics
CSL Behring
CVie Therapeutics
Daewoong
Daiichi Sankyo
Defiante Farmaceutica
Delenex Therapeutics
Dendreon (defunct, assets acquired by Valeant)
Domantis (acquired by GSK)
Dr. Reddy's Laboratories
Dutalys (acquired by Roche)
Dyax Corporation
Eddingpharm
Eisai
Eli Lilly and Company (Lilly)
Emergent BioSolutions
ESBATech (part of Novartis)
ETH Zurich
FivePrime Therapeutics
Fresenius Biotech (part of Neopharm)
F-star
Fujifilm Diosynth Biotechnologies
GE Healthcare
Genentech (subsidiary of Roche)
Genmab
Gilead Sciences
Glenmark
Glycart (acquired by Roche)
Glycotope
Goodwin Biotechnology
GSK
Hospira (acquired by Pfizer)
IBC Pharmaceuticals (majority owned by Immunomedics)
Igenica
Immunocore
ImmunoGen
Immunomedics
Intas Biopharmaceuticals
Isu Abxis
Janssen Biotech (subsidiary of Johnson & Johnson)
Kalobios
Kyowa Hakko Kirin
Kyowa Medex (subsidiary of Kyowa Hakko Kirin)
LFB
Lindis Biotech
Lonza
MacroGenics
MedImmune (subsidiary of AstraZeneca)
Menarini
Mentrik Biotech
Merck & Co.
Merck Serono
Merrimack Pharmaceuticals
Mersana Therapeutics
Merus
Micromet (acquired by Amgen)
Millennium Pharmaceuticals (subsidiary of Takeda)
Mitsubishi Tanabe
Molecular Partners
MorphoSys
MultiCell Immunotherapeutics
Neopharm
Novartis
Novartis Institutes for BioMedical Research
Novellus Biopharma
NovImmune
Ono Pharmaceutical
Oxford BioMedica
Oxford BioTherapeutics
Oxis Biotech
PDL BioPharma (part of AbbVie)
Pfizer
Pharmacyclics
Pharming Group
Pieris
Piramal Enterprises
PolyTherics
Probiomed
Progenics Pharmaceuticals
ProStrakan (acquired by Kyowa Hakko Kirin)
Redwood Science (acquired by Catalent)
Roche
Salix
Sanofi
Scil Proteins (owned by BioNet Ventures)
Seattle Genetics
Servier
Shire
Sigma-Aldrich Fine Chemicals (SAFC)
Sorrento Therapeutics
Spectrum Pharmaceuticals
Spirogen
Stelis Biopharma (subsidiary of Strides Arcolab)
Strides Arcolab
Sutro Biopharma
Swedish Orphan Biovitrum (Sobi)
Synthon
Takeda
Talon Therapeutics
Teva
TG Therapeutics
TRION Pharma
Trion Research
UCB
Wyeth (acquired by Pfizer)
Xencor
Zydus Cadila

【レポートのキーワード】

次世代抗体療法、抗体薬物複合体(ADC)、エンジニアード抗体、二重特異性抗体、抗体断片、ALP、バイオシミラー抗体、抗体治療

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[次世代抗体療法の世界市場:抗体薬物複合体(ADC)、エンジニアード抗体、二重特異性抗体、抗体断片/ALP、バイオシミラー抗体]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。H&I文字はH&Iグローバルリサーチ株式会社の商標(登録第5783645号)です。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。
※当サイトでは2016年06月27日現在 193,799 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆